A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors	Advanced Solid Tumor	Recruiting	Phase 1 / Phase 2	2026-06-15		NCT06253130

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Eikon Therapeutics	7
Impact Therapeutics, Inc.	4

57 results · Page 1 of 3

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Advent Health Research Institute	Celebration	United States	1
Cayuga Medical Center	Ithaca	United States	8
CHA Bundang Medical Center, CHA University	Seongnam-si	South Korea	6
Chongqing University Cancer Hospital	Chongqing	China	2
CLCC François Baclesse	Caen	France	1
Clínica Universidad de Navarra - Hospital	Pamplona	Spain	2
Cross Cancer Institute	Edmonton	Canada	146
Fudan University Shanghai Cancer Center	Shanghai	China	12
Fujian Cancer Hospital	Fuzhou	China	3
Fundacion MD Anderson Cancer Center	Madrid	Spain	2
Gachon University - Gil Medical Center	Incheon	South Korea	1
Gold Coast Private Hospital	Southport	Australia	1
Henry Ford Health	Detroit	United States	75
Hoag Health Center Irvine	Irvine	United States	6
Hospices Civils de Lyon - CHU Lyon Sud	Pierre-Bénite	France	1
Hospital Clinico San Carlos	Madrid	Spain	12
Hospital Clinico Universitario de Valencia - INCLIVA	Valencia	Spain	1
Hospital Del Mar	Barcelona	Spain	98
Hospital Universitari Parc Taulí	Sabadell	Spain	3
Institut Gustave Roussy	Villejuif	France	113
John Theurer Cancer Center	Hackensack	United States	20
Karmanos Cancer Institute	Detroit	United States	153
Lifespan Cancer Institute	Providence	United States	13
Macquarie University	Sydney	Australia	1
Mater Cancer Care Centre, Mater Misericordiae Limited	South Brisbane	Australia	1

Clinical trials